NOV Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? NOV Inc. Common Stock trades at $18.75 (market cap $6.76B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: NOV Inc. Common Stock is far larger — about 4.6× uniQure N.V. Ordinary Shares's market cap, and NOV Inc. Common Stock pays a 1.9% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold NOV Inc. Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NOV | QURE | |
|---|---|---|
Market Cap | $6.76B | $1.48B |
Volume | 2,412,554 | 2,488,780 |
Sector | Energy | Health |
52-Week High | $21.71 | $70.59 |
52-Week Low | $12.66 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.92B | $728.62M |
Dividend Yield | 1.9% | — |
Signals from Pluang's Aura AI — not financial advice
NOV trades at $18.96, up 0.37% with a bearish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates but showing revenue decline. Valuation metrics show a high P/E ratio of 70.22 but attractive P/S of 0.81, while profitability remains weak with 1.1% net margin. Recent news highlights strong subsea demand but Middle East risks and weak equipment sales.
The outlook is cautious with analyst consensus at $21.80 target (15% upside) but technical weakness. Investment opportunity lies in energy equipment strength and margin improvements, while risks include geopolitical exposure, competitive pressures, and inconsistent earnings performance. The stock faces headwinds from capital spending constraints in the oilfield sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
NOV provides technology, equipment, and services for energy production. Its offerings support drilling, well construction, and production across oil, gas, renewables, and emerging energy markets.
Read more on NOV →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →